{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/69cbcfb74bc3c0b5cea89f0c/6a02f57e37a1e7308de66628?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Glucocorticoids to reduce PPI after TAVI: the GLUCO-TAVI randomised trial: Original Research","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/69cbcfb74bc3c0b5cea89f0c/1778578807085-1869a5c2-924d-48cb-8e97-d8e0f5d06144.jpeg?height=200","description":"<p>In this episode of Editor’s Choice, Dr Aaysha Cader speaks with Dr Juan Miguel Ruiz-Nodar about the results of the GLUCO-TAVI trial, recently published in EuroIntervention.</p><p><br></p><p>They discuss the impact of glucocorticoid therapy on reducing permanent pacemaker implantation (PPI) following TAVI, highlighting a 50% relative risk reduction at one month. Dr Ruiz-Nodar also shares insights into the mechanisms behind these findings and outlines plans for a larger randomised trial to confirm the results and define optimal dosing and treatment duration.</p>","author_name":"EuroIntervention"}